As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...

Novavax (NASDAQ:NVAX) shares traded marginally higher on Thursday in the premarket after the Gaithersburg, Maryland-based ...

The federal government has cancelled a deal with vaccine maker Novavax to manufacture COVID-19 vaccine in Montreal, the company said in a filing with the U.S. securities regulator.

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for ...

Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Finally, for Nuvaxovid product sales. During the first half of 2025, Novavax will continue to sell Nuvaxovid in the US as it transitions the market to Sanofi, beginning with the 2025-'26 ...

Novavax (NVAX) stock jumped today following the release of the vaccine maker’s Q4 2024 earnings report. That follows its diluted earnings per ...

Novavax's stock was flat in premarket trading Thursday. The company's Matrix-M adjuvant, which helped to improve the efficacy of the company's COVID-19 vaccine, Nuvaxovid, has helped seal two ...

Novavax (NASDAQ: NVAX) signed a deal worth at least $1.2 billion with French drugmaker Sanofi (EPA: SASY) in May to hand over ...